NewAmsterdam Pharma to Merge With SPAC Frazier Lifesciences

NewAmsterdam Pharma Holding B.V. has agreed to merge with special-purpose acquisition company Frazier Lifesciences Acquisition Corp.

The deal, which is scheduled to close in the second half of 2022, is expected to form a new company called NewAmsterdam Pharma Co. N.V., which will be led by current NewAmsterdam Chief Executive Michael Davidson, the companies said Monday. The shares are expected to trade on the Nasdaq under the ticker symbol NAMS.